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at 1 h post-treatment. This finding corroborated the hepatic 
endogenous metabolic profile which showed depletion of 
glutathione from 1 h onwards. In contrast, AMAP glutath-
ionyl conjugates were not detected, nor was AMAP-induced 
depletion of hepatic glutathione observed. APAP adminis-
tration induced significant endogenous hepatic metabolic 
perturbations, primarily linked to oxidative and energetic 
stress, and perturbation of amino acid metabolism. Early 
depletion of glutathione was followed by depletion of addi-
tional sulfur-containing metabolites, while altered levels of 
mitochondrial and glycolytic metabolites indicated a disrup-
tion of energy homeostasis. In contrast, AMAP administra-
tion caused minimal, transient, distinct metabolic perturba-
tions and by 6 h the metabolic profiles of AMAP-treated 
mice were indistinguishable from those of controls.
Keywords N-acetyl-p-aminophenol (APAP) · N-acetyl-
m-aminophenol (AMAP) · Metabonomics/Metabolic 
Phenotyping · Nuclear magnetic resonance spectroscopy · 
Hepatotoxicity
Introduction
Paracetamol otherwise known as acetaminophen or 
N-acetyl-p-aminophenol (APAP) is a commonly used anal-
gesic and antipyretic drug that can cause extensive liver 
damage after an excessive dose and is the leading cause of 
drug-induced liver injury in the USA (Lee 2012). Conse-
quently, it has been extensively studied and is classified as 
a ‘model hepatotoxin’ given the extensive knowledge of its 
mechanism of hepatotoxicity (McGill et al. 2012a; Russ-
mann et al. 2009).
APAP predominantly undergoes conjugation via glucu-
ronidation or sulphation in the liver (>90 % of a therapeutic 
Abstract The leading cause of drug-induced liver injury 
in the developed world is overdose with N-acetyl-p-ami-
nophenol (APAP). A comparative metabonomic approach 
was applied to the study of both xenobiotic and endogenous 
metabolic profiles reflective of in vivo exposure to APAP 
(300 mg/kg) and its structural isomer N-acetyl-m-aminophe-
nol (AMAP; 300 mg/kg) in C57BL/6J mice, which was 
anchored with histopathology. Liver and urine samples were 
collected at 1 h, 3 h and 6 h post-treatment and analyzed 
by 1H nuclear magnetic resonance (NMR) spectroscopy and 
gas chromatography–mass spectrometry (liver only). His-
topathology revealed the presence of centrilobular necrosis 
from 3 h post-APAP treatment, while an AMAP-mediated 
necrotic endpoint was not observed within the timescale of 
this study, yet two of five treated mice showed minimal cen-
trilobular eosinophilia. The 1H-NMR xenobiotic metabolic 
profile of APAP-treated animals comprised of mercapturate 
(urine and liver) and glutathionyl (liver) conjugates detected 
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dose). Cytochrome P450 enzymes, principally CYP2E1 
(rodents and humans) and CYP3A4 (humans), are respon-
sible for oxidation of APAP to its reactive metabolite, 
N-acetyl-p-benzoquinone imine (NAPQI) (Dahlin and Nel-
son 1982; Miner and Kissinger 1979). NAPQI is a potent 
oxidant and electrophile, which leads to glutathione deple-
tion, as this represents the primary conjugation and detoxi-
fication mechanism, but also protein thiol oxidation, cross-
linking and arylation (Bessems and Vermeulen 2001; Miner 
and Kissinger 1979).
NAPQI has also been shown to covalently bind to 
mitochondrial proteins (Halmes et al. 1996; Landin et al. 
1996), and this is considered to be an important hallmark 
of APAP-induced hepatotoxicity (Jaeschke et al. 2012). 
Physiologically, the mitochondria display an altered mor-
phology, including an abrupt increase in volume as a result 
of mitochondrial membrane transition pore opening (Masu-
buchi et al. 2005; Pierce et al. 2002). Functionally, there is 
an overall disruption as reflected by mitochondrial oxida-
tive stress, ATP pool depletion and lower respiration rates 
(Katyare and Satav 1989; Placke et al. 1987), together with 
DNA fragmentation mediated by the translocation of nucle-
ases located in the mitochondrial inter-membrane space 
(Bajt et al. 2006).
N-acetyl-m-aminophenol (AMAP), a reportedly non-
hepatotoxic regioisomer of APAP in mice and hamsters 
(Nelson 1980; Roberts and Jollow 1978), has been used in 
comparative studies with APAP (Beyer et al. 2007; Hadi 
et al. 2013; Howell et al. 2014; Stamper et al. 2010). The 
comparison of regioisomers with differential toxic liabili-
ties presents significant potential for elucidating mecha-
nisms of toxicity. AMAP is thought to be less hepatotoxic 
than APAP because it binds to mitochondrial proteins to a 
lesser extent and primarily binds to cytosolic and micro-
somal proteins (Streeter et al. 1984; Tirmenstein and Nel-
son 1989). However, recent evidence suggests that AMAP 
is toxic in precision-cut liver slices from rats and humans 
(Hadi et al. 2013), and primary human hepatocytes (Xie 
et al. 2015), and therefore, further work is required to 
understand the differential toxicology of the regioisomers 
across and within species.
Metabonomics is a ‘top-down’ system approach used 
to describe the metabolic phenotype of biological samples 
under specific biological conditions or in response to an 
intervention (Nicholson et al. 1999). Metabonomics (and 
the related field of metabolomics) has found widespread 
application in the investigation of molecular toxicology, 
where the site- and mechanism-specific effects of a toxin 
or therapeutic intervention can be investigated (Coen 2014; 
Coen et al. 2008; Lindon et al. 2005). Earlier metabonomic 
studies have been applied to investigate the metabolism 
of APAP in both in vivo models and humans (Bales et al. 
1984; Nicholls et al. 1995; Spurway et al. 1990). More 
recently, studies of APAP in mice reported a significant per-
turbation of metabolites involved in the biosynthesis of glu-
tathione; opthalmate, 5-oxoproline and taurine (Soga et al. 
2006; Ghauri et al. 1993), as well as numerous system-level 
metabolic changes that together suggested a disturbance of 
energy metabolism, more specifically of increased rates 
of glycolysis and impaired β-oxidation (Coen et al. 2003, 
2004). Further evidence for APAP-induced inhibition of 
fatty acid β-oxidation includes the observation of elevated 
levels of serum long-chain acyl-carnitines in mice (Chen 
et al. 2009) and children (Bhattacharyya et al. 2014).
Here we describe the results of a multiplatform meta-
bonomic study, using gas chromatography–mass spectrom-
etry (GC–MS) and 1H nuclear magnetic resonance (NMR) 
spectroscopy to characterize the system-level xenobiotic 
metabolic profile together with the hepatic endogenous 
metabolic consequences of APAP and AMAP administra-
tion in mice, with a particular focus on the identification 
of differential discriminatory metabolites reflective of mito-
chondrial function and oxidative stress.
Materials and methods
Animal handing and treatment
Male C57BL/6J mice (n = 50, aged 10 weeks) purchased 
from Jackson Laboratory (Bar Harbor, ME, USA) were 
kept in a pathogen-free environment at the University of 
Washington. The animals were housed in Association for 
Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC)-accredited temperature-con-
trolled rooms with a 12-h light/dark cycle throughout the 
study. They were acclimated to the facility for 1 week dur-
ing which they had access to ad libitum rodent chow diet 
and acidified sterile water (pH = 2.77). All experiments 
were conducted under protocol approved by the Institu-
tional Animal Care and Use Committee of the University 
of Washington.
After a fasting period of 12 h, the mice were treated with 
APAP (300 mg/kg in saline; n = 15), AMAP (300 mg/kg 
in saline; n = 15) or sterile saline (control; n = 20), via I.P. 
injections of 15 μl/g body weight. The selected APAP dose 
has been previously reported to cause marked liver damage 
in mice (Masubuchi et al. 2005; McGill et al. 2012b) and 
an equimolar dose of AMAP was selected for comparative 
purposes which has previously been reported to be non-
toxic in this strain of mice (Fountoulakis et al. 2000; Priya-
darsiny et al. 2008). Food was returned to mice after APAP/
AMAP administration.
Mice from each treatment group were euthanized via 
CO2 inhalation and cervical dislocation at 1 h, 3 h and 6 h 
post-treatment (1 h, 3 h and 6 h, respectively; n = 5 for 
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drug treatment groups at each time-point and n = 6, n = 7 
and n = 7 for the control groups at 1 h, 3 h and 6 h, respec-
tively). At each time-point, blood from a cardiac puncture 
was collected into serum separator tubes (Microtainer, BD 
Biosciences, San Jose, California, USA) together with liver 
sections from the left lateral lobe, which were immediately 
snap-frozen in liquid nitrogen and stored at −80 °C. Sera 
fractions were collected following incubation of the col-
lected blood at room temperature (30 min) and centrifu-
gation (4000×g for 6 min). Urine was collected on ice in 
conical tubes containing sodium azide (1 mL, 1 % w/v 
water) across the following time periods: 0–1, 1–3 and 
3–6 h (n = 3 for APAP- and AMAP-treated groups at 1 h 
and n = 5 for all other groups).
Liver histopathology
Liver tissue sections from the medial lobe were fixed in 
10 % paraformaldehyde (formalin) overnight prior to 
dehydration, paraffin embedding and staining with hema-
toxylin and eosin (H&E). These were examined using 
light microscopy, and the extent of centrilobular necrosis 
was assessed without any prior knowledge of the treatment 
class. The histopathological findings were carried out for 
all treated animals and one control per time-point and were 
graded as recommended in current guidelines for report-
ing these changes (Ward and Thoolen 2011). The scoring 
criteria for centrilobular necrosis were as follows: 0 (no 
lesion), 1 (necrosis of single layer of cells around the cen-
tral vein affecting <20 % of the central veins in the liver 
lobes; minimal), 2 (necrosis of single layer of hepatocytes 
around all of the central veins in the liver lobes; mild) and 
3 (necrosis of 2–4 layers of hepatocytes around all of the 
central veins in most liver lobes; moderate). The histo-
pathological analysis also included assessment and grad-
ing of periportal glycogen, focal mixed inflammatory 
reaction, centrilobular eosinophilia and panlobular fat vac-
uolation with the analysis for individual animals provided 
in the Suppl. material (Table 1) together with the grading 
explanations.
1H‑NMR spectroscopy of the hepatic aqueous 
soluble component
Liver tissue metabolite extraction for 1H-NMR spectro-
scopic analysis was performed according to the protocol 
described by Beckonert et al. (2007). Briefly, ice-cold ace-
tonitrile/water (1.5 mL, 1:1) was added to the liver tissue 
samples (average weight of 41.4 mg and STD ± 3.1 mg. 
The samples were homogenized with 5 mm stainless steel 
beads in a homogenizer (Qiagen Tissue Lyser, Retsch 
GmBH, Haan, Germany) at 25 Hz for 8 min. The samples 
were then kept on ice for 10 min prior to centrifugation 
at 17,000×g for 15 min at 4 °C (Biofuge Pico, Heraeus, 
Hanau, Germany). The supernatant was concentrated 
and dried overnight in a centrifugal evaporator (Speed-
Vac, Thermoscientific, Waltham, Massachusetts, USA) at 
30 °C. The resultant dried supernatant was reconstituted 
in phosphate buffer (600 μL of a 0.2 M solution contain-
ing 99.9 % D2O, 3 mM sodium azide (NaN3) and 1 mM 
3-(trimethylsilyl)-[2,2,3,3-2H4]-propionic acid sodium salt 
(TSP)), vortexed for 30 s and then centrifuged at 17,000xg 
for 15 min at 4 °C (Biofuge Pico). The supernatant (550 
μL) was placed in 5 mm NMR tubes (outer diameter; 
NMR Precision tube 507-HP-7, Norell, Landisville, New 
Jersey, USA). NMR spectral data were acquired on a 
Bruker Avance-600 spectrometer operating at 600.13 MHz 
(14.1 T) 1H frequency and at a temperature of 300 K 
using a Bruker TXI probe (Bruker Biospin, Rheinstetten, 
Germany) and an automated sample handling carousel 
(Bruker). A standard one-dimensional solvent suppres-
sion pulse sequence was used to acquire the free induction 
decay (FID; relaxation delay—90° pulse—4 μs delay—90° 
pulse–mixing time–90° pulse–acquire FID) (Beckonert 
et al. 2007). The D2O present in the buffer provided a field 
frequency lock, whilst the TSP served as the chemical shift 
reference compound (δ1H = 0.00). For each experiment, 
256 transients were collected into 64,000 data points using 
a spectral width of 12,000 Hz, with a relaxation delay of 
4 s, mixing time of 100 ms and an acquisition time of 4.5 s.
1H‑NMR spectroscopy of urine
Urine samples were prepared for 1H-NMR spectroscopy as 
previously described (Beckonert et al. 2007). Briefly, urine 
was mixed with phosphate buffer (2:1, 600 μL total vol-
ume; same buffer with the hepatic aqueous extract analy-
sis) and vortexed for 1 min. The samples were then centri-
fuged at 17,000×g for 15 min at 4 °C (Biofuge Pico) and 
the supernatants (550 μL) transferred to 5 mm NMR tubes 
(507-HP-7). 1H-NMR spectral data were acquired on a 
Bruker Avance-600 spectrometer as described for the aque-
ous hepatic extracts.
1H‑NMR spectral data processing
The 1H-NMR spectra were initially processed in TopSpin 
3.0 NMR Software (Bruker), where a line-broadening 
factor of 0.3 Hz was applied to all spectra prior to Fou-
rier transformation (FT). The spectra were then manually 
phased, baseline-corrected and referenced to the TSP peak 
for the aqueous soluble liver extract and urine spectra or 
lactate peak for the sera spectra. Full-resolution 1H-NMR 
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data were imported into MATLAB (R2012, Mathworks 
Inc., Natick, Massachusetts, USA), using an in-house 
script, for further processing, which included the removal 
of the TSP and water resonance regions before performing 
probabilistic quotient normalization (Dieterle et al. 2006). 
This is a robust method of normalization which corrects 
for the differential dilution of urine samples, a factor which 
affects the concentration of all metabolites or intensity of 
all resonances in a spectrum. This dilution factor correc-
tion thus enables the detection of the biologically relevant, 
relative concentration changes in selected metabolites. The 
method scales the spectra based on the most probable dilu-
tion factor, calculated from the distribution of quotients of 
the intensity of each spectral data point relative to a refer-
ence spectrum. This method has shown to be more robust 
for normalization of metabolic profiling data sets than total 
area integral normalization (Dieterle et al. 2006). Spectral 
metabolite assignments were achieved using Statistical 
TOtal Correlation Spectroscopy (STOCSY) (Cloarec et al. 
2005), 2D-NMR experiments (Correlation Spectroscopy), 
spectral databases (Human Metabolome Database and 
Biological Magnetic Resonance Bank), software includ-
ing Chenomx NMR Suite (Chenomx, Edmonton, Alberta, 
Canada) and previously published assignments (Nicholson 
et al. 1995). Furthermore, the following hepatic metabo-
lites were identified by ‘spike-in’ experiments with the pure 
standard compounds: adenosine monophosphate (AMP), 
succinate, 2-aminoadipate, dimethylamine, phosphocho-
line, choline and glutathione (reduced and oxidized). A 
summary of the integral regions of the endogenous metabo-
lites and the drug-related resonances is displayed in Table 2 
and Table 3 in the Suppl. material, respectively. Finally, the 
assignment of APAP and AMAP metabolites was based on 
existing literature (Bales et al. 1984; Nicholls et al. 2006).
In-house scripts were used to calculate the integral of 
resonances belonging to drug related, and parent com-
pounds in both treatment groups at 1 h (n = 3 for each 
group), in order to estimate their relative abundance to 
the parent molecule. The integrated resonances in the 
hepatic extract 1H-NMR profiles were as follows: APAP 
parent (δ1H = 7.26; doublet), APAP glucuronide conju-
gate (δ1H = 7.15; doublet), APAP glutathionyl conjugate 
(δ1H = 6.96; doublet), APAP-N-acetylcysteinyl conju-
gate (δ1H = 1.85; singlet), AMAP glucuronide conjugate 
(δ1H = 7.24; singlet) and AMAP parent (δ1H = 7.03; 
singlet). The resonances used in the urine 1H-NMR meta-
bolic profiles were as follows: APAP parent (δ1H = 6.88; 
doublet), APAP glucuronide conjugate (δ1H = 7.36; dou-
blet), APAP sulfate conjugate (δ1H = 7.31; doublet), APAP 
cysteinyl conjugate (δ1H = 7.50; singlet), APAP-N-acetyl-
cysteinyl conjugate (δ1H = 1.86; singlet), AMAP glucuro-
nide conjugate (δ1H = 7.24; singlet), AMAP sulfate con-
jugate (δ1H = 7.43; triplet), AMAP parent (δ1H = 7.02; 
singlet) and APAP methoxy conjugate (δ1H = 3.88; sin-
glet). Each integral was adjusted for the equivalent num-
ber of protons before the ratio to the parent molecule was 
calculated. Finally, the integral of the resonances belonging 
to endogenous metabolites were also calculated, includ-
ing total glutathione (oxidized and reduced; δ1H = 2.55; 
multiplet), succinate (δ1H = 2.41; singlet), 2-aminoadipate 
(δ1H = 2.25; triplet), glutamate (δ1H = 2.35; multiplet), 
d-3-Hydroxybutyrate (d-3-HB; δ1H = 1.20; doublet), glu-
cose (δ1H = 5.25; doublet), AMP (δ1H = 8.61; singlet) and 
valine (δ1H = 1.04; doublet).
GC–MS analysis of the hepatic aqueous soluble 
component
Liver tissue samples of an average weight of 25.25 mg 
and STD of ±0.22 mg were added to an ice-cold HPLC-
grade water/methanol mixture (1:1, 1.2 mL total volume) 
and homogenized with zirconia beads at 6500 Hz (Pre-
cellys, Montigny-le-Bretonneux, France) for two 45-s peri-
ods with an intermediate 5-min cooling period on dry ice. 
The homogenized mixtures were incubated for 45 min on 
ice before centrifugation at 17,000×g for 15 min at 4 °C 
(Biofuge Pico). The resulting supernatant was mixed with 
ice-cold methanol/water (2:1, 0.5 mL) to facilitate protein 
precipitation. The samples were then incubated overnight at 
−4 °C and centrifuged the following day at 17,000×g for 
15 min at 4 °C (Biofuge Pico).
Quality control (QC) samples were prepared by collect-
ing and pooling 5 µL aliquots from each sample prior to 
drying overnight in a centrifugal concentrator (SpeedVac). 
The resulting dried supernatants were then derivatized using 
the methoximation/silylation protocol provided by Fiehn 
(2008). Briefly, myristic-d27 acid (5 µL of a 6-mM solution 
in anhydrous pyridine) and U-13C-d-Glucose (20 µL of a 
1-mM solution in anhydrous pyridine) were added as stand-
ards to each sample for retention time locking and quanti-
fication purposes, respectively. For the methoximation step, 
methoxyamine hydrochloride (40 µL of 0.3 M solution in 
anhydrous pyridine) was added to each sample and the sam-
ples were then incubated at 30 °C for 90 min with shaking 
at 30-min intervals. For the silylation step, the samples were 
incubated with N-methyl-N-(trimethylsilyl)-trifluoroaceta-
mide (90 µL; MSTFA) at 37 °C for 30 min. Finally, 2-fluoro-
biphenyl (10 µL of a 1-mM solution in anhydrous pyridine) 
was added as an injection standard.
GC–MS analysis was performed on an Agilent 7890 gas 
chromatograph coupled to a 5975 mass selective detector 
(MSD) quadruple mass spectrometer (MSD; Agilent Tech-
nologies, Santa Clara, California, USA) in accordance with 
the Fiehn protocol (Fiehn 2008). QC samples were used at 
the beginning of the run to condition the chromatographic 
column and thereafter at five sample intervals (Sangster et al. 
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2006). The acquired spectra were initially processed with the 
Automated Mass Spectral Deconvolution and Identification 
System software (AMDIS, NIST, Gaithersburg, Maryland, 
USA) by using the Fiehnlib library (Kind et al. 2009). The 
spectra were then transferred to MATLAB (Mathworks), 
and an in-house developed MATLAB script was then used 
to manually inspect the chromatographic peaks of the identi-
fied metabolites and remove all of the features that were not 
consistently present in the QC samples, before integration of 
the remaining features (Behrends et al. 2011).
Overall, the analysis led to the analysis of 38 molecular 
species which were subsequently tested for statistically sig-
nificant differences between treatment groups. Reasons for 
metabolite exclusion prior to analysis included poor chro-
matographic peak shape, peak overlap and an inconsistent 
presence in the spectra of QC samples. The 38 selected 
metabolites were normalized through the fitting of QC-
derived polynomial curves for each metabolic feature (Dunn 
et al. 2011) followed by log median factor normalization to 
account for inter-batch effects. The overall normalization 
process was evaluated by principal component analysis 
(PCA) to explore the effect of each normalization step on 
the inherent clustering (biochemical similarity) of samples.
Statistical analysis
Prism 5.0 (Graphpad; La Jolla, CA, USA) was used for 
nonparametric univariate analysis of the 1H-NMR spectro-
scopic analysis (Kruskal–Wallis with Dunn’s multiple test 
correction) and for parametric analysis of the log-trans-
formed GC–MS data (analysis of variance (ANOVA) with a 
Bonferroni multiple correction test). A significance thresh-
old value of p < 0.05 was set throughout. Please note that 
inter-time-point statistical comparisons were avoided due 
to the fluctuating metabolite levels in the control cohorts 
over time, such as those of glucose and AMP. Furthermore, 
six liver samples (n = 3 for control at 1 h, n = 1 for APAP 
at 3 h, n = 1 for control at 6 h and n = 1 for AMAP at 6 h) 
were excluded from the 1H-NMR spectroscopic analysis 
as they were identified as outliers following a preliminary 
Fig. 1  Representative histopathology slides of the APAP-, AMAP-
treated and control groups at 6 h. No visible damage is present in the 
control group (a), panlobular fat vacuolation is visible in the AMAP-
treated group (b; arrowhead) and centrilobular necrosis is present in the 
APAP-treated group (c; arrows). A summary of the centrilobular necro-
sis scores of the AMAP- and APAP-treated groups is presented in d 
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Fig. 2  Representative 1H-NMR spectra of hepatic extract meta-
bolic profiles of the APAP, AMAP and control groups at 1 h. Reso-
nances assigned to drug-related molecules have been colored in red. 
Key: APAP/AMAP-G, APAP/AMAP glucuronide; APAP-SG, APAP 
glutathionyl; APAP-NAC, APAP-N-acetylcysteinyl; APAP/AMAP-
NHCOCH3, APAP/AMAP N-acetyl resonance; GSH, reduced glu-
tathione; GSSG, oxidized glutathione; Phe, phenylalanine; d-3-HB, 
d-3-hydroxybutyrate; AMP, adenosine monophosphate, overlapped 
resonances from glucose/glycogen/maltose labelled
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Fig. 3  Integrals of discriminatory metabolites identified by the 1H-
NMR spectroscopic analysis of hepatic extracts after APAP/AMAP 
administration (A). Drug metabolite ratios of APAP and AMAP con-
jugates to their respective parent molecules in the hepatic extract and 
urinary metabolic profiles at the 1-h time-point are also shown (B). 
Kruskal–Wallis test coupled to Dunn’s multiple test correction was 
used to calculate the statistical significance of endogenous metabolic 
perturbations, which is indicated by the asterisks, * and ** (p < 0.05 
and p < 0.01, respectively). Key -SG, glutathionyl conjugate; -S, sul-
fate conjugate; -G, glucuronide conjugate; -Cys, cysteinyl conjugate; 
-NAC, N-acetylcysteinyl conjugate
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principal component analysis due to poor spectral quality. 
Finally, the urine metabolic profiles were not analyzed sta-
tistically due to insufficient numbers per treatment group 
per time-point, as a result of insufficient volume collected 
from the animals within the short time-collection windows.
Results
Liver histopathology
Mice given APAP showed histopathological changes at 
all time-points examined. At 1 h, one of the treated mice 
showed a grade 1 centrilobular eosinophilia, while a second 
animal showed a grade 2 panlobular fat vacuolation (Suppl. 
Table 1). Two of the APAP-treated animals showed grade 
1 focal inflammatory cell infiltration at 1 h post-treatment.
At 3 h, all examined animals showed centrilobular eosino-
philia of grades 3–4 and two of these animals with grade 4 cen-
trilobular eosinophilia showed a grade 1 centrilobular necrosis.
At 6 h, four of the five livers examined showed centri-
lobular eosinophilia of grades 3–4 and three of the five liv-
ers examined showed centrilobular necrosis of grades 2–3 
(Suppl. Table 1). Figure 1 provides a representative slide of a 
control (1A), AMAP (1B)- and APAP (1C)-treated animal at 
6 h post-treatment showing the presence of the centrilobular 
necrotic lesion (grade 3) following APAP treatment. A sum-
mary of the centrilobular necrosis scores at all time-points in 
the AMAP- and APAP-treated mice is presented in Fig. 1d.
Mice given AMAP did not show any histological 
changes at time-point 1 h, but at both time-points 3 h and 
6 h the livers of two of five treated mice showed a grade 
1 and grade 2 centrilobular eosinophilia while at time-
point 6 h one of the mice with centrilobular eosinophilia 
also showed a grade 2 panlobular fat vacuolation (Suppl. 
Table 1). Two of the AMAP-treated animals showed a 
grade 1 focal inflammatory cell infiltration at all time-
points, whereas an additional animal showed a grade 1 
focal inflammatory cell infiltration at 1 h and 6 h post-
treatment (Suppl. Table 1).
APAP and AMAP metabolism in C57BL/6J mice
The metabolism of APAP and AMAP was characterized in 
hepatic extracts and urine from the 1D 1H-NMR spectro-
scopic profiles. In the hepatic extracts, APAP and its glucu-
ronide, glutathionyl and N-acetylcysteinyl conjugates were 
observed at 1 h (Figs. 2, 3b). In the case of AMAP-treated 
hepatic extract profiles, the unchanged parent and AMAP 
glucuronide were the only compounds detected at the equiv-
alent time-point (Figs. 2, 3b). The urinary 1H-NMR spectro-
scopic metabolic profiles revealed the presence of the APAP 
parent and the APAP glucuronide, sulfate, N-acetylcysteinyl 
and cysteinyl conjugates at 1 h (Suppl. Fig. 1 and Fig. 3b). 
In the AMAP-treated mice, the unchanged parent and the 
glucuronide and sulfate conjugates were detected, but there 
was no evidence for the excretion of glutathionyl-conjugated 
compounds (Suppl. Fig. 1 and Fig. 3b). The AMAP glucuro-
nide conjugate was the most abundant metabolite in all sam-
ple matrices, while the APAP glutathionyl and glucuronide 
conjugates were the most abundant compounds detected in 
liver and urine samples from APAP-dosed mice. These data 
are presented as metabolite/parent ratios for both liver and 
urine in Fig. 3b. Lower levels of the xenobiotic metabolites 
were also detected in the urinary metabolic profiles of the 
APAP (cysteinyl, glucuronide and sulfate conjugates)- and 
AMAP-treated mice (glucuronide conjugate) at 3 h. 
1H‑NMR spectroscopic detected endogenous 
changes in hepatic extracts following AMAP 
and APAP administration
Representative 1H-NMR spectra of hepatic extracts from each 
treatment group and a control are given in Fig. 2 showing the 
respective assignment of the key xenobiotic and endogenous 
Table 1  Summary of discriminatory metabolites identified by 1H-NMR spectroscopic analysis of hepatic extracts after APAP/AMAP adminis-
tration
Treatment
group
Time-points
1 h 3 h 6 h
APAP Glutathione*
Succinate*
2-Aminoadipate**
Glutamate*
Valine*
Glutathione*
2-Aminoadipate*
Glutamate*
Valine*
D-3-HB*
Glucose*
AMP**
AMAP
No significant 
changes
No significant 
changes
No significant 
changes
Kruskal–Wallis test coupled to Dunn’s multiple test correction was used to calculate the statistical significance, which is indicated by the aster-
isks, * and ** (p < 0.05 and p < 0.01, respectively). Key: d-3-HB—d-3-hydroxybutyrate
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metabolites. Univariate analysis revealed that APAP admin-
istration led to the depletion of glutathione (reflecting both 
oxidized and reduced forms) at 1 h and 3 h, while succinate, 
valine, 2-aminoadipate and glutamate were elevated at 3 h, 
relative to controls. At 6 h post-treatment, the APAP-treated 
mice showed elevation of 2-aminoadipate, glutamate, d-3-HB 
and valine, while AMP and glucose were depleted relative to 
controls. In contrast to APAP, AMAP administration did not 
lead to any statistically significant metabolic differences in 
the 1H-NMR metabolic profiles, relative to controls, through-
out the time course of the study. The integrals and sum-
mary of the statistically significant differences identified by 
1H-NMR spectroscopy are presented in Fig. 3a and Table 1, 
respectively. Table 4 in the Suppl. material displays the 
Fig. 4  Integrals of discriminatory metabolites identified by GC–MS 
analysis of the hepatic extracts after APAP/AMAP administration. 
ANOVA coupled to Bonferroni multiple test correction was used. 
Statistical significance is shown by the asterisks, * and ** (p < 0.05 
and p < 0.01, respectively)
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individual 1H-NMR resonance integral values for all metabo-
lites analyzed.
GC–MS‑detected endogenous changes in hepatic 
extracts after AMAP and APAP administration
The GC–MS analysis of the hepatic extracts indicated that 
APAP treatment resulted in elevated quantities of xanthine, 
guanosine and nicotinamide at 1 h, together with reduced 
levels of hypotaurine, tryptophan and thymine at 3 h, rela-
tive to the controls. At 6 h post-treatment, lower amounts 
of hypotaurine, adenosine, methionine, AMP, aspartate and 
tyrosine were observed, while hepatic concentrations of 
phosphoenolpyruvate, 3-phosphoglycerate and uracil had 
increased relative to the control mice. The parallel analysis 
of the AMAP-treated groups revealed elevation of guano-
sine at 1 h relative to control mice. There were no statisti-
cally significant metabolic perturbations at either the 3- or 
6-h time-points following AMAP treatment. The integrals 
and summary of the GC–MS-detected statistically sig-
nificant hepatic metabolic perturbations induced by both 
AMAP and APAP are presented in Fig. 4 and summarized 
in Table 2, respectively. Table 5 in the Suppl. material dis-
plays the individual GC–MS integral values for all metabo-
lites analyzed.
Discussion
The simultaneous characterization of xenobiotic metabo-
lism and endogenous metabolic perturbations induced by 
AMAP and APAP treatment was achieved using a combi-
nation of 1H-NMR and GC–MS analysis. This comparative 
metabonomic approach provided complementary mecha-
nistic insight into the adaptation of hepatic metabolism to 
toxic insult and enabled the identification of unique meta-
bolic phenotypes for each treatment. Following APAP 
administration, glutathione conjugates were detected at 1 h 
post-treatment in the hepatic extracts (APAP glutathionyl, 
APAP-N-acetylcysteinyl) and urinary metabolic profiles 
(APAP cysteinyl and APAP-N-acetylcysteinyl), reflect-
ing both the production and detoxification of the electro-
philic reactive metabolite of APAP, NAPQI. This corrobo-
rated the marked depletion of hepatic glutathione (sum of 
reduced and oxidized forms) at 1 h and 3 h post-treatment. 
This depletion will have likely led to further downstream 
metabolic effects, such as the GC–MS-detected depletion 
of hepatic hypotaurine at 3 h and 6 h and methionine at 6 h 
post-treatment, which are precursors of glutathione. This 
may reflect the cellular response to APAP-induced oxida-
tive stress which has been previously reported to lead to the 
depletion of sulfur-containing metabolites such as hypotau-
rine (Soga et al. 2006; Yamazaki et al. 2013) and methio-
nine (Yamazaki et al. 2013) (Fig. 5).
The observed hepatic elevation of the mitochondrial 
metabolite succinate, at 3 h post-treatment, as well as glu-
tamate at 3 h and 6 h post-treatment, suggested APAP-
induced mitochondrial dysfunction as a key event in the 
onset of hepatotoxicity. These perturbations which pre-
ceded the histopathological observation of necrosis may 
reflect mitochondrial disruption as a result of the inability 
of mitochondria to utilize tricarboxylic acid cycle interme-
diates (Burcham and Harman 1991). APAP administration 
has been previously demonstrated to up-regulate succi-
nate dehydrogenase (a component of the electron transport 
chain) in C57BL/6 mice, which would affect succinate lev-
els (Stamper et al. 2011). Finally, disruption of the tricarbo-
xylic acid cycle and the previously reported APAP-induced 
disruption of glutamate dehydrogenase (Halmes et al. 
1996) could also be responsible for the observed elevation 
of hepatic glutamate.
Impaired mitochondrial respiration and ATP synthesis 
in response to APAP exposure would lead to the up-regu-
lation of other energy-related pathways (Katyare and Satav 
Table 2  Summary of discriminatory metabolites identified by GC–MS analysis of the hepatic extracts after APAP/AMAP administration
APAP
Guanosine*
Xanthine*
Nicotinamide*
Hypotaurine**
Thymine*
3-PG*
PEP**
Uracil*
Thymine*
AMP*
IMP*
Adenosine*
Methionine*
Aspartate*
AMAP Guanosine*
1 h 3 h 6 h
No significant 
changes
No significant 
changes
Treatment
group
Time-points
ANOVA coupled to Bonferroni multiple test correction was used. Statistical significance is shown by the asterisks, * and ** (p < 0.05 and 
p < 0.01, respectively). Key: IMP—inosine monophosphate; AMP—adenosine monophosphate; PEP—phosphoenolpyruvate; 3-PG—3-phos-
phoglycerate
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1989). The depletion of glycogen and glucose coupled 
with the elevation of d-3-HB seen in the hepatic 1H-NMR 
metabolic profiles at 6 h post-treatment provides evidence 
of the energetic stress exerted by APAP (Coen et al. 2003). 
This finding suggests a possible shift from mitochondrial 
oxidative phosphorylation to glycolysis and supports ear-
lier metabonomic-based study findings (Coen et al. 2003, 
2004). This shift could also explain the higher levels of 
hepatic phosphoenolpyruvate and 3-phosphoglycerate that 
were detected by GC–MS analysis at the same time-point 
(Fig. 5).
Finally, APAP was also observed to induce a decrease 
in the hepatic concentration of guanosine at 1 h (GC–MS 
analysis) and AMP (1H-NMR and GC–MS analyses) and 
adenosine (GC–MS analysis) at 6 h post-treatment. APAP 
has previously been reported to affect nucleoside and 
nucleotide metabolism through the inhibition of enzymes 
such as adenosine deaminase (Ataie et al. 2004); how-
ever, the exact mechanism is uncertain. It is possible that 
the observed hepatic effect could be linked to the deple-
tion of ATP levels and the subsequent utilization of adenine 
nucleotides in the liver in an attempt to compensate for 
energy loss (Tirmenstein and Nelson 1990). The panel of 
APAP-induced discriminatory metabolites and associated 
metabolic pathways identified in this work is summarized 
in Fig. 5.
In contrast to APAP, the histopathological analysis 
suggested that AMAP administration (300 mg/kg) did 
not lead to hepatotoxicity in the form of centrilobular 
necrosis within the 6-h timescale studied. The absence of 
AMAP glutathionyl conjugates in the hepatic and urinary 
profiles and the absence of perturbation of endogenous 
hepatic glutathione contrasted with APAP and suggested 
the absence of AMAP-induced oxidative stress, which 
could explain the difference in toxicity between the two 
compounds (Hamilton and Kissinger 1986). This find-
ing is in agreement with previous findings which showed 
the urinary excretion of the cysteinyl and mercapturic 
acid conjugates of AMAP represented 5 % of the dose 
(600 mg/kg, male Swiss Webster mice). In contrast, uri-
nary excretion of the cysteinyl and mercapturic acid 
conjugates of APAP represented ca. 20 % of the dose 
(250 mg/kg) (Rashed et al. 1990). Assuming that admin-
istration of these isomers at the same doses results in 
equivalent hepatic exposures, such a result could simply 
reflect differences in their propensities for bioactivation, 
or alternatively their relative affinities for alternative 
routes of metabolism, such as glucuronidation, that result 
in detoxification.
Following treatment with AMAP, discriminatory metab-
olites were identified at the earliest 1 h post-treatment time-
point with metabolic homeostasis restored at 3 h and 6 h 
post-treatment, when 1H-NMR spectroscopic profiles of 
AMAP-treated animals were indistinguishable from con-
trols. The histopathology analysis revealed that two ani-
mals developed hepatic grade 1 and 2 centrilobular eosino-
philia at the 6-h time-point. The presence of centrilobular 
eosinophilia suggests that AMAP administration may have 
led to centrilobular necrosis at a later time-point in these 
two animals. However, within our 6-h equimolar dose com-
parative study, AMAP was not found to have in common 
any metabolic perturbations identified in the APAP-treated 
mice, which included markers for the development of oxi-
dative stress and mitochondrial dysfunction.
In summary, we applied a comparative metabonomic 
approach to generate metabolic phenotypes of AMAP and 
APAP exposure, which was anchored with traditional his-
topathological assessment. APAP administration caused 
oxidative stress at an early time-point and subsequently 
induced energetic stress as evidenced from the impairment 
Fig. 5  Summary of hepatic metabolic perturbations associated with 
APAP-induced mitochondrial dysfunction and oxidative stress. Dia-
grammatic representations of the glycolysis pathway (a) and tricar-
boxylic acid cycle (b), as well as the methionine–homocysteine 
cycle and glutathione synthesis (c) are shown. Red shading depicts 
an APAP-induced elevation, while blue shading represents an APAP-
induced depletion. Key d-3-HB, d-3-hydroxybutyrate (color figure 
online)
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of mitochondrial function and up-regulation of glycolysis. 
AMAP was observed to have an early, transient, metabolic 
effect that was reversible by 6 h and did not lead to a hepa-
totoxic endpoint.
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